MoonLake Immunotherapeutics
MLTXHealthcare|Biotechnology|Switzerland
$20.36
+0.43 (+2.18%)
Tangible Book
$3.52
Earnings Power
$3.55
Upcoming Data Readouts (3)
Sep 2026
Est. completion
P3Hidradenitis Suppurativa
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671n=35
Jan 2027
Est. completion
P3Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089n=600
Feb 2027
Est. completion
P3Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641076n=960